Gaucher Disease ( GBA ) Sequencing
Ordering Recommendation
Carrier screening or diagnostic testing for GD in individuals of non-Ashkenazi Jewish descent.
New York DOH Approval Status
Specimen Required
Lavender (K2 or K3EDTA), pink (K2EDTA), or yellow (ACD solution A or B).
New York State Clients: Lavender (EDTA)
Transport 3 mL whole blood. (Min: 1 mL)
Refrigerated.
New York State Clients: Ambient
Ambient: 1 week; Refrigerated: 1 month; Frozen: Unacceptable
New York State Clients: Ambient: 4 days; Refrigerated: Unacceptable; Frozen: Unacceptable
Methodology
Sequencing / Polymerase Chain Reaction (PCR)
Performed
Varies
Reported
14-21 days
Reference Interval
Refer to report
Interpretive Data
Background information for Gaucher Disease ( GBA) Sequencing:
Characteristics: Gaucher disease (GD) is a lysosomal storage disorder with phenotypes ranging from perinatal lethality to lack of symptoms. There are three GD subtypes. Type 1 GD manifests with bone disease, hepatosplenomegaly, anemia, thrombocytopenia, and lung disease but no central nervous system (CNS) involvement. Type 2 GD exhibits CNS symptoms before age 2 and rapidly progresses, resulting in death by age 4. Type 3 GD presents as early as age 2 with CNS symptoms that slowly progress resulting in death during the third or fourth decade.
Incidence: 1 in 900 Ashkenazi Jewish individuals; approximately 1 in 57,000 to 1 in 75,000 in general population.
Inheritance: Autosomal recessive.
Cause: Two pathogenic GBA variants on opposite chromosomes.
Clinical Sensitivity: 99 percent.
Methodology: Long-range PCR followed by bidirectional sequencing of all coding regions and intron-exon boundaries of the GBA gene.
Analytical Sensitivity and Specificity: A pproximately 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region variants, deep intronic variants, large deletions/duplications/insertions, gene conversion, and complex gene events may not be detected.
Laboratory Developed Test (LDT)
Note
When testing cord blood specimens, the presence of maternal cell contamination (MCC) is possible, which may impact result interpretation. If clinically warranted, testing for MCC is available, at a charge, through ARUP Laboratories.
Hotline History
CPT Codes
81479
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 3001649 | GBA FGS- Specimen | 31208-2 |
| 3001650 | GBA FGS Interpretation | 46988-2 |
Aliases
- Beta-glucocerebrosidase deficiency
- Beta-Glucosidase
















